Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes.
about
FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activityHistone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alphaClass IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactinTranscriptional activation of hypoxia-inducible factor-1alpha by HDAC4 and HDAC5 involves differential recruitment of p300 and FIH-1Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator TatHDAC inhibitors as anti-inflammatory agentsThe endothelium abridges insulin resistance to premature agingMonitoring the effect of belinostat in solid tumors by H4 acetylationSequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspectiveHDAC and HDAC Inhibitor: From Cancer to Cardiovascular DiseasesDevelopment, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1Epigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor HypoxiaTargeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implicationsEpigenetics in Brain Tumors: HDACs Take Center StageThe tissue-specific methylation of the human tyrosine hydroxylase gene reveals new regulatory elements in the first exonArrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1alpha and is not induced by hypoxia or HIFCarboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancerEffects of histone deacetylase inhibitors on HIF-1DNA methyltransferase 3b regulates nerve growth factor-induced differentiation of PC12 cells by recruiting histone deacetylase 2Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway.A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions.Inverse Association between Sodium Channel-Blocking Antiepileptic Drug Use and Cancer: Data Mining of Spontaneous Reporting and Claims Databases.Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1).Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumorsQuisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma.Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinaseRNA-seq analysis of the functional compartments within the rat placentation site.Hypoxic repression of endothelial nitric-oxide synthase transcription is coupled with eviction of promoter histonesEpigenetic drugs can stimulate metastasis through enhanced expression of the pro-metastatic Ezrin gene.Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas.AngioDB: database of angiogenesis and angiogenesis-related moleculesPhase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.Anti-tumor mechanisms of valproate: a novel role for an old drug.New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer.The hypoxia-inducible epigenetic regulators Jmjd1a and G9a provide a mechanistic link between angiogenesis and tumor growth.Histone modification enzymes: novel targets for cancer drugs.Histone deacetylases regulate gonadotropin-releasing hormone I gene expression via modulating Otx2-driven transcriptional activity.
P2860
Q24291819-954E61DC-A63A-449B-89C5-BD2F849EB3DEQ24308024-F9B5EC53-B040-495C-8DA0-9FDFD122AECAQ24322940-3D819A11-EB89-44FA-96C2-CEC0630F6778Q24324150-5AD212BC-23A5-4A0C-851C-F3D7D09BEE95Q24537275-2E528450-F6C7-4EF1-BBAD-2EFB3BB05D09Q24564962-B897A381-3B81-4AF9-942C-2C4F8E2B227BQ24605364-40392014-E075-4B6B-8BF1-82E3D3720960Q24644030-94807713-88A8-4F60-9843-59DA5DE3F501Q26744089-16372566-6F60-40D2-881B-781BC40C802EQ26766640-F6E4E55C-02CE-461F-A7A4-3529DD2A4B52Q26778957-F7405403-A7FC-4B04-92F5-D6D1BE944C47Q26783014-A190FD5D-BE54-4ABD-89B2-722B3E8098F2Q26853394-0FFB14C2-B1B6-43EE-B68F-48CAEC361C01Q28080964-1E5347A8-39C9-44F6-966B-FB01CFE8CC55Q28256201-2467BFCF-BE1E-45AD-9113-8DC8E3B16EB2Q28259619-33C7214F-38BB-44E9-9C73-B2E07B9B420CQ28265589-8DC54FB4-3232-4A0C-BD5E-B69E528B79A0Q28273896-EC690A31-7E46-4379-B021-DBE0735A5A4DQ28584099-73A9D193-8D11-4A24-9168-CE277EB7B522Q30310695-FDB277F6-35F8-41A4-9A11-3B5034E41CE1Q30538453-D5A46F84-737F-4242-A82E-0893DEC1FBDEQ30873726-AE97DDC7-AAA4-4811-B88F-1B96544FBEA8Q31040399-17FF92F3-79EF-4FEB-9E6A-981C708CA14CQ33235403-9B0B784B-0B5D-4F65-B755-FAEC1DCF6DC6Q33391851-7411B5F4-53B4-414B-AA3B-25A8FD54D365Q33402040-134152BA-A1FC-4D6C-A999-7EB2F6962822Q33429115-DEC9C4F4-97D3-4C04-A1B9-48EB8C593AACQ33521840-8E7DBBA6-BAA2-4542-AE33-D106467F10CFQ33569578-BDF32F8E-91CC-4B1A-B299-6C26D666EB7FQ33569829-A5DE253F-F9A4-41CD-AA0D-82DF07CF8082Q33698044-B7257F47-292F-41F8-892B-FDB7E5125168Q33860585-9B6377D1-AF60-479D-8428-2EC0150CCB0BQ34010714-B0A19FBD-3B6F-43D6-988A-6B005FCD5E0AQ34107482-97306C8E-A2B2-47D6-9EF4-E4F3757CB909Q34147644-F610BA11-8E19-47F6-BD38-93F5C426F793Q34224278-D7D84941-FA23-4EB9-9B56-130C6FD44DE2Q34240470-01F2DED2-AC0C-4529-B196-17E68D6B37B7Q34298049-4C0906AB-7F9C-4027-B5F7-E3D2E373D42FQ34322087-C53330C8-6059-4647-986E-982AE9A601B1Q34326508-6C1A5635-CFB8-4DF4-88B9-18400DA653FB
P2860
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Histone deacetylases induce an ...... ion of tumor suppressor genes.
@ast
Histone deacetylases induce an ...... ion of tumor suppressor genes.
@en
type
label
Histone deacetylases induce an ...... ion of tumor suppressor genes.
@ast
Histone deacetylases induce an ...... ion of tumor suppressor genes.
@en
prefLabel
Histone deacetylases induce an ...... ion of tumor suppressor genes.
@ast
Histone deacetylases induce an ...... ion of tumor suppressor genes.
@en
P2093
P356
P1433
P1476
Histone deacetylases induce an ...... ion of tumor suppressor genes.
@en
P2093
P2888
P304
P356
10.1038/86507
P407
P577
2001-04-01T00:00:00Z
P5875
P6179
1023141012